Fenski Maximilian, Abazi Endri, Gröschel Jan, Hadler Thomas, Kappelmayer Diane, Kolligs Frank, Prieto Claudia, Botnar Rene, Kunze Karl-Philipp, Schulz-Menger Jeanette
Working Group Cardiovascular Magnetic Resonance, Experimental and Clinical Research CenterMax-Delbrück Center for Molecular MedicineDepartment of Cardiology and Nephrology, Charité Medical Faculty, HELIOS Klinikum Berlin Buch, Charité - Universitätsmedizin Berlin Lindenberger Weg 80, 13125, Berlin, Germany.
Department of Internal Medicine and Gastroenterology, HELIOS Klinikum Berlin Buch, Berlin, Germany.
Clin Res Cardiol. 2024 Aug 5. doi: 10.1007/s00392-024-02503-5.
BACKGROUND: Active inflammatory bowel disease (A-IBD) but not remission (R-IBD) has been associated with an increased risk of cardiovascular death and hospitalization for heart failure. OBJECTIVES: Using cardiovascular magnetic resonance (CMR), this study aims to assess adverse myocardial remodeling in patients with IBD in correlation with disease activity. METHODS: Forty-four IBD patients without cardiovascular disease (24 female, median-age: 39.5 years, 26 A-IBD, 18 R-IBD) and 44 matched healthy volunteers (HV) were prospectively enrolled. The disease stage was determined by endoscopic and patient-reported criteria. Participants underwent CMR for cardiac phenotyping: cine imaging and strain analysis were performed to assess ventricular function. T1 mapping, extracellular volume and late-gadolinium enhanced images were obtained to assess focal and diffuse myocardial fibrosis. Simultaneous T1 and T2 elevation (T1 > 1049.3 ms, T2 > 54 ms) was considered to indicate a myocardial segment was inflamed. RESULTS: 16/44 (16.4%) IBD patients described dyspnea on exertion and 10/44 (22.7%) reported chest pain. A-IBD patients showed impaired ventricular function, indicated by reduced global circumferential and radial strain despite preserved left-ventricular ejection fraction. 16% of all IBD patients had focal fibrosis in a non-ischemic pattern. A-IDB patients had increased markers of diffuse left ventricular fibrosis (T1-values: A-IBD: 1022.0 ± 34.83 ms, R-IBD: 1010.10 ± 32.88 ms, HV: 990.61 ± 29.35 ms, p < .01). Significantly more participants with A-IDB (8/26, 30.8%) had at least one inflamed myocardial segment than patients in remission (0/18) and HV (1/44, 2.3%, p < .01). Markers of diffuse fibrosis correlated with disease activity. CONCLUSION: This study, using CMR, provides evidence of myocardial involvement and patterns of adverse left ventricular remodeling in patients with IBD. CLINICAL TRIAL REGISTRATION: ISRCTN30941346.
背景:活动性炎症性肠病(A-IBD)而非缓解期炎症性肠病(R-IBD)与心血管死亡及因心力衰竭住院风险增加相关。 目的:本研究旨在使用心血管磁共振成像(CMR)评估炎症性肠病患者的不良心肌重塑及其与疾病活动度的相关性。 方法:前瞻性纳入44例无心血管疾病的炎症性肠病患者(24例女性,中位年龄:39.5岁,26例A-IBD,18例R-IBD)和44例匹配的健康志愿者(HV)。通过内镜检查和患者报告的标准确定疾病阶段。参与者接受CMR心脏表型分析:进行电影成像和应变分析以评估心室功能。获取T1映射、细胞外容积和延迟钆增强图像以评估局灶性和弥漫性心肌纤维化。同时T1和T2升高(T1>1049.3毫秒,T2>54毫秒)被认为表明心肌节段有炎症。 结果:16/44(16.4%)的炎症性肠病患者描述有劳力性呼吸困难,10/44(22.7%)报告有胸痛。A-IBD患者显示心室功能受损,尽管左心室射血分数保留,但整体圆周应变和径向应变降低表明了这一点。所有炎症性肠病患者中有16%有非缺血性模式的局灶性纤维化。A-IDB患者弥漫性左心室纤维化标志物增加(T1值:A-IBD:1022.0±34.83毫秒,R-IBD:1010.10±32.88毫秒,HV:990.61±29.35毫秒,p<0.01)。与缓解期患者(0/18)和HV(1/44,2.3%)相比,A-IDB患者中有更多参与者(8/26,30.8%)至少有一个心肌节段有炎症(p<0.01)。弥漫性纤维化标志物与疾病活动度相关。 结论:本研究使用CMR提供了炎症性肠病患者心肌受累及左心室不良重塑模式的证据。 临床试验注册:ISRCTN30941346。
JACC Cardiovasc Imaging. 2025-6
Cochrane Database Syst Rev. 2021-11-29
JACC Cardiovasc Imaging. 2018-8
Eur Heart J. 2023-10-1
JACC Cardiovasc Imaging. 2023-4
Reumatol Clin (Engl Ed). 2023-1
Eur Heart J Open. 2021-10-14
Front Cardiovasc Med. 2022-7-14